Cargando…

EFFICACY OF BARICITINIB IN PATIENTS TREATED WITH CORTICOSTEROIDS FOR SEVERE COVID-19 PNEUMONIA: A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

INTRO: Current evidence is still lacking in use of baricitinib among COVID-19 patients that require low flow oxygen and have systemic inflammation. Therefore, we are keen to evaluate the efficacy of baricitinib therapy among this group of patients, in preventing progression into high flow oxygen dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tay, K.H., Sim, L.H. Benedict, Chidambaram, S.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186886/ http://dx.doi.org/10.1016/j.ijid.2023.04.239

Ejemplares similares

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
por: Pérez-Alba, Eduardo, et al.
Publicado: (2021)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study
por: Obradović, Dušanka, et al.
Publicado: (2023)

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

Treatment of severe alopecia areata with baricitinib
por: Olamiju, Brianna, et al.
Publicado: (2019)

Severity of community-acquired pneumonia treated with low-dose adjunctive corticosteroid
por: Mikami, Katsunaka, et al.
Publicado: (2011)

507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study
por: Dea, Lauren, et al.
Publicado: (2021)

A severe case of acute exogenous lipoid pneumonia treated with systemic corticosteroid
por: Yasui, Hideki, et al.
Publicado: (2016)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
por: Goletti, Delia, et al.
Publicado: (2021)

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
por: Titanji, Boghuma K, et al.
Publicado: (2020)

Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh
por: Hasan, Md. Jahidul, et al.
Publicado: (2021)

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro
por: Dong, Jie, et al.
Publicado: (2022)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
por: Yasuda, Yuto, et al.
Publicado: (2022)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
por: Roddy, John, et al.
Publicado: (2022)

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis
por: Song, Wenxin, et al.
Publicado: (2023)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

CORTICOSTEROID TREATMENT IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
por: Hong, Gloria, et al.
Publicado: (2020)

Corticosteroids as Adjunctive Therapy in Severe Community-Acquired Pneumonia
por: Cillóniz, C., et al.
Publicado: (2016)

Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
por: Sun, Ziyi, et al.
Publicado: (2023)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
por: Faria, Sofia, et al.
Publicado: (2023)

NZ's Pharmac to fund baricitinib for moderate-to-severe COVID-19
Publicado: (2021)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Inhaled Corticosteroids in Asthma and the Risk of Pneumonia
por: Kim, Min-Hye, et al.
Publicado: (2019)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report
por: Qi, Jia-Ping, et al.
Publicado: (2023)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Severe psittacosis progressing to suspected organizing pneumonia and the role of corticosteroids
por: Zuzek, Rachael, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
por: Thoms, Brendan L., et al.
Publicado: (2022)

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19
por: Richardson, Peter J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bot1bb20orcav91se1eoos5f31